Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA.
- DOI
- 10.1016/j.esmogo.2026.100416
- Published
- 2026 Dec
- Container
- ESMO gastrointestinal oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmogo.2026.100416,
title = {Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA.},
author = {Inagaki C and Oki E and Ando K and Hirano H and Furuta M and Narita Y and Esaki T and Murotani K and Kawakami H and Muro K},
year = {2026},
journal = {ESMO gastrointestinal oncology},
doi = {10.1016/j.esmogo.2026.100416},
url = {https://doi.org/10.1016/j.esmogo.2026.100416}
}RIS
TY - JOUR TI - Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA. AU - Inagaki C AU - Oki E AU - Ando K AU - Hirano H AU - Furuta M AU - Narita Y AU - Esaki T AU - Murotani K AU - Kawakami H AU - Muro K PY - 2026 JO - ESMO gastrointestinal oncology DO - 10.1016/j.esmogo.2026.100416 UR - https://doi.org/10.1016/j.esmogo.2026.100416 ER -
APA
C, I., E, O., K, A., H, H., M, F., Y, N., T, E., K, M., H, K., & K, M. (2026). Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA.. ESMO gastrointestinal oncology. https://doi.org/10.1016/j.esmogo.2026.100416
Source records
- pubmed · retrieved 2026-09-25T18:32:29.215Z